41,700 Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Purchased by KLP Kapitalforvaltning AS

KLP Kapitalforvaltning AS acquired a new position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 41,700 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,508,000. KLP Kapitalforvaltning AS owned 0.08% of Supernus Pharmaceuticals at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Smartleaf Asset Management LLC boosted its holdings in shares of Supernus Pharmaceuticals by 219.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company’s stock worth $47,000 after purchasing an additional 870 shares during the period. Newbridge Financial Services Group Inc. purchased a new position in shares of Supernus Pharmaceuticals during the 4th quarter valued at $72,000. Venturi Wealth Management LLC purchased a new position in shares of Supernus Pharmaceuticals during the 4th quarter valued at $92,000. KBC Group NV raised its holdings in shares of Supernus Pharmaceuticals by 53.1% during the fourth quarter. KBC Group NV now owns 2,679 shares of the specialty pharmaceutical company’s stock worth $97,000 after acquiring an additional 929 shares in the last quarter. Finally, Janney Montgomery Scott LLC acquired a new position in Supernus Pharmaceuticals in the 4th quarter worth about $211,000.

Supernus Pharmaceuticals Stock Performance

Supernus Pharmaceuticals stock opened at $32.29 on Friday. The business’s 50-day simple moving average is $35.15 and its 200-day simple moving average is $35.01. Supernus Pharmaceuticals, Inc. has a 52 week low of $25.53 and a 52 week high of $40.28. The firm has a market capitalization of $1.80 billion, a PE ratio of 30.18 and a beta of 0.83.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on SUPN. Cantor Fitzgerald reissued a “neutral” rating and issued a $36.00 price target on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th. StockNews.com downgraded Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, March 24th.

Insiders Place Their Bets

In other news, VP Padmanabh P. Bhatt sold 700 shares of the company’s stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $39.62, for a total transaction of $27,734.00. Following the completion of the transaction, the vice president now owns 10,149 shares of the company’s stock, valued at approximately $402,103.38. This represents a 6.45 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Jonathan Rubin sold 927 shares of Supernus Pharmaceuticals stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $39.15, for a total value of $36,292.05. Following the sale, the senior vice president now directly owns 7,853 shares in the company, valued at approximately $307,444.95. This trade represents a 10.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 11,104 shares of company stock valued at $440,263 in the last three months. Company insiders own 9.30% of the company’s stock.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.